Amia Capital LLP Macrogenics Inc Transaction History

Amia Capital LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$19.41 - $26.0 $468,382 - $627,406	-24,131 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$24.69 - $31.6 $31,405 - $40,195	-1,272 Reduced 5.01%	24,131 $608,000
Q2 2020 Aug 14, 2020	SELL	$5.2 - $29.12 $72,727 - $407,272	-13,986 Reduced 35.51%	25,403 $709,000
Q1 2020 May 15, 2020	SELL	$4.28 - $12.11 $22,508 - $63,686	-5,259 Reduced 11.78%	39,389 $229,000
Q4 2019 Feb 13, 2020	BUY	$7.95 - $12.27 $354,951 - $547,830	44,648 New	44,648 $486,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Amia Capital LLP, based on Form 13F filings with the SEC.

Stay updated on Amia Capital LLP with notifications on news.